The London and Cambridge Life Sciences Team advised Closed Loop Medicine Ltd on its oversubscribed £13 million financing from a range of top UK and European venture capital investors. The round was led by Anada Impact Ventures and BGF, joined by a syndicate with medial research charity LifeArc and institutional investors including Longwall Venture Partners, Meltwind, IQ Capital, Downing Ventures and Cambridge Angels.
The investment will fund further product development.
Closed Loop Medicine is a UK-based global leader in the development of single prescription drug plus digital therapy (DTx) combination products to enable precision dosing.
For more information see here.